从细分产品单点突破，到依托技术同源横向拓展，是不少中国企业的成长路径。成立于2001年的伟思医疗，就是沿着这一 路径发展。从国内盆底及产后康复领域的领先者，到"康复＋医美"双轮驱动，再到在脑机接口等前沿技术方向探索，公司 实现了单一业务到多元布局的产品线跨越。 医疗器械市场空间巨大，随着老龄化速度加快、慢性病管理需求增加，市场需求持续增长。然而"红海"的另一面是，医疗 器械也是一个"长坡厚雪"的赛道，研发投入大、回报周期长，对于企业而言是耐心和战略的考验。 盆底及产后康复，是伟思医疗的起家业务，也是公司最重要的"护城河"之一。2009年起，在中国盆底康复市场还处于萌芽 期时，伟思医疗就持续投入研发，先后搭建了电刺激、磁刺激、电生理等核心技术平台，并成功推出了盆底功能磁刺激仪 等多款核心产品。公司先后进入精神心理康复、盆底及产后康复、神经康复等核心赛道，形成差异化优势。 ◎记者 操子怡 不过，随着企业规模扩大，传统的业务市场容量逐渐显露天花板，公司开始思考：能否把磁刺激、电刺激等底层技术用于 更多治疗场景？ 她表示，近三年来，公司研发投入比例稳定在15%以上，处于行业较高水平。此外，公司很多产品集中于精神疾病诊 ...

Core Viewpoint - Weisi Medical emphasizes its commitment to research and innovation as the driving force behind its competitive advantage in the rehabilitation medical device sector [1] Group 1: Company Overview - Weisi Medical is a technology-driven enterprise in the domestic rehabilitation medical device field, focusing on continuous R&D investment and precise market positioning [1] - The company has established significant competitive advantages in various niche markets, maintaining excellent profitability and market share [1] Group 2: Product Coverage and Market Position - The company's products cover a wide range of domestic medical institutions, including general hospitals, obstetrics, psychiatry, pediatrics, and rehabilitation specialty hospitals [1] - In key niche markets such as pelvic and postpartum rehabilitation, mental health, and pediatric rehabilitation, Weisi Medical ranks among the top domestic manufacturers [1] - Core products like transcranial magnetic stimulators, pelvic magnetic stimulators, and group biofeedback devices are leading in market sales compared to similar products [1] Group 3: Future Strategy - Looking ahead, the company plans to strengthen its R&D engine, accelerate the localization of high-end equipment, and deepen the layout of rehabilitation clinical solutions [1] - The goal is to consolidate its position as a technology leader in the industry and to drive the overall upgrade of China's rehabilitation medical industry [1]

Core Viewpoint - Weisi Medical (688580) has experienced a decline in stock price, with a current market capitalization of 4.587 billion yuan, ranking 79th in the medical device sector and 3616th in the A-share market [1] Group 1: Stock Performance - As of November 14, 2025, Weisi Medical's stock closed at 47.9 yuan, down 2.68% from the previous week [1] - The stock reached a high of 50.25 yuan on November 10 and a low of 47.36 yuan on November 13 [1] Group 2: Shareholder Changes - On November 12, 2025, Weisi Medical announced that shareholder Nanjing Zhida Venture Capital Center (Limited Partnership) reduced its holdings by 448,600 shares, accounting for 0.4684% of the total share capital, during a period when the stock price fell by 7.58% [2] - From August 14 to November 11, 2025, the same shareholder reduced its holdings by a total of 1,176,782 shares, representing 1.2287% of the total share capital, with a reduction price range of 45.00 to 57.50 yuan per share, totaling approximately 59.52 million yuan [3][4] - The shareholder's stake decreased from 8.29% to 7.06%, and the actual reduction aligned with the previously disclosed plan [3][4]

Trading Information Summary - On November 12, 2025, Weisi Medical (688580) closed at 48.2 yuan, with a slight increase of 0.06% and a turnover rate of 1.97% [1] - The trading volume was 18,800 shares, with a total transaction value of 91.6083 million yuan [1] - On the same day, the net inflow of main funds was 15.4231 million yuan, accounting for 16.84% of the total transaction value [3] Shareholder Changes - On November 12, 2025, Weisi Medical announced that shareholder Nanjing Zhida Venture Capital Center (Limited Partnership) reduced its holdings by 448,600 shares between November 5 and November 11, representing 0.4684% of the company's total share capital [2] - The share price during this period decreased by 7.58%, closing at 48.17 yuan on November 11 [2] - From August 14 to November 11, the shareholder cumulatively reduced its holdings by 1,176,782 shares, accounting for 1.2287% of the total share capital, with a reduction price range of 45.00 to 57.50 yuan per share, totaling approximately 59.516 million yuan [2][3]

Core Viewpoint - The announcement details the completion of a share reduction plan by a major shareholder of Weisi Medical, indicating the amount and method of shares sold, as well as the overall impact on the company's total share capital [1][3]. Summary by Sections Shareholder Reduction Overview - The shareholder, Nanjing Zhida Venture Capital Center (Limited Partnership), held 7,935,120 shares prior to the reduction, representing 8.29% of the total share capital of Weisi Medical [2]. Implementation Results of the Reduction Plan - The reduction plan was disclosed on July 23, 2025, with a timeframe set from August 14, 2025, to November 11, 2025. The shareholder planned to reduce up to 2,873,137 shares, which would account for a maximum of 3% of the total share capital. This included a maximum of 957,712 shares through centralized bidding (1% of total shares) and 1,915,425 shares through block trading (2% of total shares) [3]. - The actual reduction results showed that from August 14 to November 11, 2025, the shareholder reduced 956,052 shares through centralized bidding (0.9983% of total shares) and 220,730 shares through block trading (0.2305% of total shares), totaling 1,176,782 shares, which is 1.2287% of the total share capital [3][4]. Additional Information - The reduction plan was fully implemented as planned, with no early termination of the plan [4].

Core Viewpoint - Weisi Medical announced the completion of the share reduction plan by its shareholder Nanjing Zhida Venture Capital Center (Limited Partnership) on November 12, as confirmed in a response to investor inquiries on the interactive platform [1] Group 1 - The share reduction plan by Nanjing Zhida Venture Capital Center has reached its deadline and is now concluded [1]

Core Viewpoint - Weisi Medical announced a significant share reduction by its shareholder Nanjing Zhida Venture Capital Center, indicating potential shifts in shareholder structure and market sentiment [1] Summary by Category Shareholder Actions - Zhida Venture Capital reduced its holdings in Weisi Medical by a total of 1,176,782 shares, which represents 1.2287% of the company's total share capital [1] - The reduction occurred between August 14, 2025, and November 11, 2025, with 956,052 shares sold through centralized bidding, accounting for 0.9983% of the total share capital, and 220,730 shares sold via block trading, representing 0.2305% of the total share capital [1]

Core Viewpoint - Weisi Medical announced a significant share reduction by its shareholder Zhida Venture Capital, which may impact the company's stock performance and investor sentiment [1] Group 1: Shareholder Activity - Zhida Venture Capital reduced its holdings in Weisi Medical by approximately 960,000 shares through centralized bidding, accounting for 0.9983% of the company's total share capital [1] - Additionally, Zhida Venture Capital sold about 220,000 shares via block trading, representing 0.2305% of the total share capital [1] - The reduction period for this shareholding plan spanned from August 14, 2025, to November 11, 2025, and has now concluded [1] Group 2: Financial Performance - For the year 2024, Weisi Medical's revenue composition is as follows: medical devices accounted for 95.03%, other businesses for 3.79%, and additional services for 1.18% [1] - As of the announcement date, Weisi Medical's market capitalization stands at 4.6 billion yuan [1]

证券代码：688580 证券简称：伟思医疗 公告编号：2025-042 南京伟思医疗科技股份有限公司 关于股东减持股份计划时间届满暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 本次减持股东持股的基本情况 本次减持计划实施前，南京伟思医疗科技股份（以下简称"伟思医疗"或"公 司"）股东南京志达创业投资中心（有限合伙）（以下简称"志达创投"）持有公 司股份 7,935,120 股，占公司总股本的 8.29%。上述股份均来源于公司 IPO 前取 得的股份以及公司实施资本公积金转股本取得的股份，均已解禁上市流通。 减持计划的实施结果情况 2025 年 7 月 23 日，公司于上海证券交易所（www.sse.com.cn）披露了《股 东减持股份计划公告》（公告编号：2025-27），志达创投计划于 2025 年 8 月 14 日至 2025 年 11 月 11 日期间，通过集中竞价、大宗交易方式减持公司股份，合 计减持不超过 2,873,137 股，合计减持比例不超过公司总股本的 3%。 ...

Core Viewpoint - Weisi Medical (688580.SH) announced a share reduction by its shareholder Zhida Venture Capital, which has implications for the company's stock performance and investor sentiment [1] Summary by Category Shareholder Actions - Zhida Venture Capital reduced its holdings in Weisi Medical by a total of 1,176,800 shares, which represents 1.2287% of the company's current total share capital [1] - The reduction occurred between August 14, 2025, and November 11, 2025, through both centralized bidding and block trading methods [1] Share Reduction Details - Specifically, Zhida Venture Capital sold 956,100 shares via centralized bidding, accounting for 0.9983% of the total share capital [1] - Additionally, 220,700 shares were sold through block trading, representing 0.2305% of the total share capital [1]